Strategic Acquisition CRELUX is part of WuXi AppTec and was acquired in 2016, indicating strong corporate backing and potential for integrated collaboration across WuXi services to drive joint drug discovery programs.

Full Service Advantage As a global provider of structure based drug discovery, X-ray crystallography, protein supply, biophysical analysis and fragment screening, CRELUX can offer end‑to‑end discovery support, enabling faster client timelines through integrated workflows.

Mid‑Market Focus With 51-200 employees and revenue in the $10M–$25M range, CRELUX represents a mid‑sized partner that can scale collaboration to fit mid‑stage to late‑stage programs, presenting a compelling balance of agility and capability.

Parent Network Leveraging WuXi AppTec’s researc h services portfolio, CRELUX can cross‑sell complementary capabilities to existing WuXi clients and access a broader ecosystem for multi‑disciplinary drug discovery engagements.

Global Presence Based in Germany with a global service orientation, CRELUX can pursue international collaborations, leveraging local proximity and European regulatory familiarity to win multinational projects.